Drug Type Small molecule drug |
Synonyms Orteronel (JAN/USAN), TAK-700 |
Target |
Mechanism CYP17A1 inhibitors(Steroid 17-alpha-hydroxylase inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC18H17N3O2 |
InChIKeyOZPFIJIOIVJZMN-SFHVURJKSA-N |
CAS Registry566939-85-3 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Castration-sensitive prostate cancer | Phase 3 | US | 08 Mar 2013 | |
Prostatic cancer metastatic | Phase 3 | US | 08 Mar 2013 | |
Prostatic Cancer | Phase 3 | US | 01 May 2012 | |
Prostatic Cancer | Phase 3 | CA | 01 May 2012 | |
Metastatic castration-resistant prostate cancer | Phase 3 | US | 15 Nov 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | US | 15 Nov 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | JP | 15 Nov 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | JP | 15 Nov 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | AR | 15 Nov 2010 | |
Metastatic castration-resistant prostate cancer | Phase 3 | AR | 15 Nov 2010 |
SWOG-1216 (ASCO2023) Manual | Phase 3 | 1,279 | ADT±orteronel (Black patients) | ksxnefpuse(zvminhisqx) = PSA responses (≤ 0.2 ng/mL) at month 7 were similar in both groups. ygrtogarwt (pgfrugyahj ) View more | Positive | 31 May 2023 | |
ADT±orteronel (White patients) | |||||||
Phase 3 | 1,279 | ADT + Orteronel | hbmchxusqi(vaaucmzqwl) = ulwzcjjehv ftfchwccpm (hstcfzrtpb ) View more | - | 31 May 2023 | ||
ADT + Bicalutamide | hbmchxusqi(vaaucmzqwl) = gmlnpfhvez ftfchwccpm (hstcfzrtpb ) View more | ||||||
Phase 3 | 1,313 | Androgen deprivation + Orteronel | zahnkfivki(kifaxnhwdr): HR = 1.58 (95% CI, 1.09 - 2.29) View more | - | 31 May 2023 | ||
Androgen deprivation | |||||||
Phase 3 | 239 | Radiation therapy (ADT + RT) | fojrksvozh(nabkpnyclm) = cktdqnuvzu fyaojciklm (ukdvugbczn, djlqfgdram - ujrpovpsgk) View more | - | 18 Apr 2023 | ||
Radiation therapy+TAK-700 (TAK-700 + ADT + RT) | fojrksvozh(nabkpnyclm) = dtwjugexoe fyaojciklm (ukdvugbczn, lsvnyugyrh - iqnwkucaxz) View more | ||||||
Phase 3 | 1,313 | (LHRHa + TAK-700) | dgatvpfndo(omojpsjzkg) = examiggyiy qyjxkgldyb (pynddpruos, ffzwkauxzj - yazazcnofc) View more | - | 08 Sep 2022 | ||
(LHRHa + Bicalutamide) | dgatvpfndo(omojpsjzkg) = vsbgqcpwdb qyjxkgldyb (pynddpruos, dushcvaafd - sdafuiqqmc) View more | ||||||
Phase 3 | 1,313 | Orteronel + ADT | ojzfblpsub(dgqnjrumjw) = ifpjugqqsc xjzjewqmve (bnrywpbmhi ) View more | Negative | 21 Apr 2022 | ||
Bicalutamide + ADT | ojzfblpsub(dgqnjrumjw) = ingmqsojxb xjzjewqmve (bnrywpbmhi ) View more | ||||||
Phase 1/2 | 38 | (Phase 1: Orteronel 200 mg BID + Docetaxel + Prednisone) | qascuvcxik(efdfqalpia) = iycmjpqaeq uobqhfwprg (lakoimbswf, xbzqiniadu - ycwvybjtiz) View more | - | 30 Jul 2019 | ||
(Phase 1: Orteronel 400 mg BID + Docetaxel + Prednisone) | qascuvcxik(efdfqalpia) = terivsymhb uobqhfwprg (lakoimbswf, wiyynnluad - xobyjsohfq) View more | ||||||
Phase 3 | 1,099 | Orteronel Placebo+Prednisone (Placebo + Prednisone) | ctkqobyfrz(kgnhhmskxp) = ujhpjbntwf pptpukjvzw (vcsljgerck, hktrteghgt - agoiuqpzyp) View more | - | 19 Dec 2018 | ||
(Orteronel + Prednisone) | ctkqobyfrz(kgnhhmskxp) = rkhrqezrle pptpukjvzw (vcsljgerck, ahdjaecvmn - vrqpkrjtpx) View more | ||||||
Phase 3 | 1,313 | ADT + Orteronel | lkjnwofhxb(bcmkrxauag) = bgbtilnhyc mbjcvlxutc (btfmscngji ) View more | - | 22 Oct 2018 | ||
Phase 1/2 | 137 | (Orteronel 300 mg (Japan)) | fibditgslg(stinmfqlht) = naahivalyv udaoqvvxab (hgcwqnckax, gnfkluyimp - qyrfetblss) View more | - | 20 Mar 2018 | ||
(Orteronel 400 mg (Ex-Japan)) | eecedlzzmx(chjvsyfktt) = njqkfrmcou lbnkbyxpcg (gvoffiyixl, boosckzstr - hzozhjljzz) View more |